Altimmune Historical Income Statement

ALT Stock

USD 7.11 0.10 1.39%

Historical analysis of Altimmune income statement accounts such as Selling General Administrative of 13.5 M, Total Revenue of 364.2 K or Other Operating Expenses of 116.3 M can show how well Altimmune performed in making a profits. Evaluating Altimmune income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Altimmune's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Altimmune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Altimmune is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

About Altimmune Income Statement Analysis

Altimmune Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Altimmune shareholders. The income statement also shows Altimmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Altimmune Income Statement Chart

At this time, Altimmune's Net Interest Income is comparatively stable compared to the past year.

Interest Expense Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Net Income

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Altimmune generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Altimmune minus its cost of goods sold. It is profit before Altimmune operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Altimmune. It is also known as Altimmune overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Altimmune financial statement analysis. It represents the amount of money remaining after all of Altimmune operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from Altimmune's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Net Interest Income is comparatively stable compared to the past year.

	2022	2023	2024	2025 (projected)
Research Development	70.5M	65.8M	75.7M	79.5M
Depreciation And Amortization	500K	477K	429.3K	435.7K

Research Development Depreciation And Amortization

Altimmune income statement Correlations

	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Depreciation And Amortization	Research Development	Total Other Income Expense Net	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Interest Expense		-0.03	-0.08	0.04	-0.22	0.22	-0.8	-0.8	0.02	-0.22	0.07	0.86	0.75	-0.17	-0.28	0.97	0.86	1.0	0.55	0.8	-0.15	-0.14	-0.13	-0.09
Selling General Administrative	-0.03		-0.05	0.05	0.81	-0.7	-0.44	-0.44	-0.17	0.81	-0.12	-0.38	0.01	-0.13	0.7	0.05	-0.37	-0.05	0.08	0.07	0.59	0.59	0.31	0.46
Total Revenue	-0.08	-0.05		0.71	-0.4	0.61	0.39	0.39	-0.11	-0.4	-0.53	0.26	-0.24	-0.15	-0.5	-0.06	0.27	-0.07	-0.43	0.0	-0.5	-0.49	-0.22	-0.33
Gross Profit	0.04	0.05	0.71		-0.19	0.42	0.16	0.16	-0.69	-0.19	-0.41	0.24	0.11	-0.28	-0.3	0.09	0.24	0.05	-0.37	0.33	-0.17	-0.15	-0.22	-0.09
Other Operating Expenses	-0.22	0.81	-0.4	-0.19		-0.9	-0.38	-0.37	-0.19	1.0	0.09	-0.63	-0.01	0.01	0.97	-0.12	-0.63	-0.24	0.05	-0.07	0.83	0.82	0.44	0.62
Operating Income	0.22	-0.7	0.61	0.42	-0.9		0.38	0.38	0.0	-0.9	-0.22	0.69	0.11	0.0	-0.93	0.2	0.68	0.25	-0.3	0.23	-0.69	-0.67	-0.44	-0.43
Ebit	-0.8	-0.44	0.39	0.16	-0.38	0.38		1.0	0.05	-0.38	-0.14	-0.4	-0.67	0.11	-0.33	-0.83	-0.4	-0.79	-0.57	-0.68	-0.29	-0.29	-0.14	-0.18
Ebitda	-0.8	-0.44	0.39	0.16	-0.37	0.38	1.0		0.05	-0.37	-0.14	-0.4	-0.67	0.12	-0.33	-0.83	-0.4	-0.79	-0.57	-0.68	-0.29	-0.29	-0.14	-0.18
Cost Of Revenue	0.02	-0.17	-0.11	-0.69	-0.19	0.0	0.05	0.05		-0.19	0.17	0.02	-0.36	0.16	-0.16	-0.09	0.03	0.01	0.35	-0.48	-0.29	-0.31	0.12	-0.21
Total Operating Expenses	-0.22	0.81	-0.4	-0.19	1.0	-0.9	-0.38	-0.37	-0.19		0.09	-0.63	-0.01	0.01	0.97	-0.12	-0.63	-0.24	0.05	-0.07	0.83	0.82	0.44	0.62
Income Before Tax	0.07	-0.12	-0.53	-0.41	0.09	-0.22	-0.14	-0.14	0.17	0.09		-0.09	0.44	0.0	0.13	0.02	-0.09	0.03	0.21	-0.03	0.15	0.14	0.13	0.09
Net Income	0.86	-0.38	0.26	0.24	-0.63	0.69	-0.4	-0.4	0.02	-0.63	-0.09		0.6	-0.13	-0.69	0.83	1.0	0.87	0.27	0.71	-0.46	-0.44	-0.32	-0.28
Income Tax Expense	0.75	0.01	-0.24	0.11	-0.01	0.11	-0.67	-0.67	-0.36	-0.01	0.44	0.6		0.0	-0.07	0.81	0.6	0.74	0.17	0.88	0.14	0.15	-0.05	0.1
Depreciation And Amortization	-0.17	-0.13	-0.15	-0.28	0.01	0.0	0.11	0.12	0.16	0.01	0.0	-0.13	0.0		0.04	-0.12	-0.14	-0.16	-0.33	0.0	0.04	0.04	0.27	-0.02
Research Development	-0.28	0.7	-0.5	-0.3	0.97	-0.93	-0.33	-0.33	-0.16	0.97	0.13	-0.69	-0.07	0.04		-0.19	-0.69	-0.3	0.05	-0.15	0.76	0.75	0.41	0.55
Total Other Income Expense Net	0.97	0.05	-0.06	0.09	-0.12	0.2	-0.83	-0.83	-0.09	-0.12	0.02	0.83	0.81	-0.12	-0.19		0.83	0.98	0.41	0.89	-0.05	-0.03	-0.1	-0.02
Net Income From Continuing Ops	0.86	-0.37	0.27	0.24	-0.63	0.68	-0.4	-0.4	0.03	-0.63	-0.09	1.0	0.6	-0.14	-0.69	0.83		0.87	0.27	0.71	-0.45	-0.44	-0.32	-0.28
Non Operating Income Net Other	1.0	-0.05	-0.07	0.05	-0.24	0.25	-0.79	-0.79	0.01	-0.24	0.03	0.87	0.74	-0.16	-0.3	0.98	0.87		0.54	0.81	-0.16	-0.15	-0.15	-0.1
Non Recurring	0.55	0.08	-0.43	-0.37	0.05	-0.3	-0.57	-0.57	0.35	0.05	0.21	0.27	0.17	-0.33	0.05	0.41	0.27	0.54		0.08	0.1	0.07	0.02	0.1
Tax Provision	0.8	0.07	0.0	0.33	-0.07	0.23	-0.68	-0.68	-0.48	-0.07	-0.03	0.71	0.88	0.0	-0.15	0.89	0.71	0.81	0.08		0.04	0.06	-0.11	0.04
Interest Income	-0.15	0.59	-0.5	-0.17	0.83	-0.69	-0.29	-0.29	-0.29	0.83	0.15	-0.46	0.14	0.04	0.76	-0.05	-0.45	-0.16	0.1	0.04		1.0	0.42	0.77
Net Interest Income	-0.14	0.59	-0.49	-0.15	0.82	-0.67	-0.29	-0.29	-0.31	0.82	0.14	-0.44	0.15	0.04	0.75	-0.03	-0.44	-0.15	0.07	0.06	1.0		0.41	0.77
Reconciled Depreciation	-0.13	0.31	-0.22	-0.22	0.44	-0.44	-0.14	-0.14	0.12	0.44	0.13	-0.32	-0.05	0.27	0.41	-0.1	-0.32	-0.15	0.02	-0.11	0.42	0.41		0.44
Extraordinary Items	-0.09	0.46	-0.33	-0.09	0.62	-0.43	-0.18	-0.18	-0.21	0.62	0.09	-0.28	0.1	-0.02	0.55	-0.02	-0.28	-0.1	0.1	0.04	0.77	0.77	0.44

Click cells to compare fundamentals

Altimmune Account Relationship Matchups

Altimmune income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	9.4K	5.7K	8K	35K	40.3K	38.2K
Selling General Administrative	13.2M	15.4M	17.1M	18.1M	20.9M	13.5M
Total Revenue	8.2M	4.4M	(68K)	426K	383.4K	364.2K
Gross Profit	(25.3M)	3.9M	(136K)	(51K)	(45.9K)	(43.6K)
Other Operating Expenses	63.0M	90.0M	87.7M	96.4M	110.8M	116.3M
Operating Income	(54.8M)	(96.9M)	(87.7M)	(95.9M)	(86.3M)	(82.0M)
Ebit	(54.5M)	(97.1M)	(84.9M)	(88.4M)	(79.6M)	(75.6M)
Ebitda	(54.2M)	(96.5M)	(84.4M)	(87.9M)	(79.1M)	(75.2M)
Cost Of Revenue	33.5M	551.3K	68K	477K	548.6K	521.1K
Total Operating Expenses	63.0M	90.0M	87.7M	96.4M	110.8M	116.3M
Income Before Tax	(54.5M)	(97.1M)	(84.9M)	(88.4M)	(101.7M)	(106.8M)
Net Income	(49.0M)	(96.2M)	(84.7M)	(88.4M)	(79.6M)	(75.6M)
Income Tax Expense	(5.4M)	(919.5K)	(197K)	309.1K	278.2K	264.3K
Depreciation And Amortization	298.1K	551.3K	500K	477K	429.3K	435.7K
Research Development	49.8M	74.5M	70.5M	65.8M	75.7M	79.5M
Total Other Income Expense Net	337.2K	(176.8K)	2.8M	7.5M	8.6M	9.7M
Net Income From Continuing Ops	(49.0M)	(97.1M)	(84.7M)	(88.4M)	(79.6M)	(75.6M)
Non Operating Income Net Other	(2.2M)	888.5K	346.7K	(171.1K)	(154.0K)	(146.3K)
Net Income Applicable To Common Shares	(21.0M)	(49.0M)	(97.1M)	(84.7M)	(76.2M)	(72.4M)
Tax Provision	(6.1M)	(58.5K)	(5.4M)	(110.3K)	(197K)	0.0
Interest Income	322.5K	202.7K	2.9M	7.4M	8.5M	8.9M
Net Interest Income	313.1K	197.1K	2.9M	7.3M	8.4M	8.8M
Reconciled Depreciation	298.1K	551.3K	(205K)	477K	548.6K	306.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Altimmune Historical Income Statement

About Altimmune Income Statement Analysis

Altimmune Income Statement Chart

Interest Expense

Total Revenue

Gross Profit

Other Operating Expenses

Net Income

Altimmune income statement Correlations

Altimmune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Altimmune income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Altimmune Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Operating Income Net Other	+ 1.0	Interest Expense
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Net Interest Income	+ 1.0	Interest Income
Non Operating Income Net Other	+ 0.98	Total Other Income Expense Net

Research Development	- 0.93	Operating Income
Total Operating Expenses	- 0.9	Operating Income
Operating Income	- 0.9	Other Operating Expenses
Total Other Income Expense Net	- 0.83	Ebitda
Total Other Income Expense Net	- 0.83	Ebit
Ebitda	- 0.8	Interest Expense